Attached files
| file | filename |
|---|---|
| 8-K - 8-K - CAREFUSION Corp | form8-kitem202707901_fy14q3.htm |
| EX-99.1 - NEWS RELEASE - CAREFUSION Corp | ex991fy14q3.htm |
Updated Fiscal 2014 Financial Guidance May 5, 2014 © 2014 CareFusion Corporation or one of its subsidiaries. All rights reserved. Exhibit 99.2
Forward-Looking Statements “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This presentation contains our fiscal 2014 financial guidance, which are forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion’s Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; and we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business. This presentation reflects management’s views as of May 5, 2014. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 2 © 2014 CareFusion Corporation or one of its subsidiaries. All rights reserved.
3 Fiscal 2014 Guidance May 5, 2014 Previous FY14 Guidance Updated FY14 Guidance Total Organic Revenue Growth (constant currency) 1-4% 2-4% Total Reported Revenue Growth (constant currency)1 4-7% 5-7% Medical Systems Revenue (constant currency) 1-4% 1-4% Procedural Solutions Revenue (constant currency)1 13-15% 15-17% Adjusted Operating Margin1,2 20.5-21.5% ~20% Adjusted Effective Tax Rate2 28-30% ~27% Adjusted Diluted EPS From Continuing Operations2 $2.30-$2.40 $2.30-$2.40 Diluted Weighted Average Shares Outstanding1,3 < 215 million < 215 million Operating Cash Flow $500-$550 million $550-$600 million Capital Expenditures ~$110 million ~$100 million 1 Previous FY14 Guidance reflects guidance provided in connection with the Q2FY14 earnings release on February 3, 2014. 2 Adjusted amounts are non-GAAP financial measures. These measures exclude amortization of acquired intangible assets, nonrecurring restructuring and acquisition integration charges, inventory evaluation step-up charges, and the tax effects of these items. In addition, adjusted financial measures exclude the impact of the $41 million reserve for expected government settlement, which we paid in January 2014. A GAAP to non-GAAP reconciliation can be found in the company’s Q3FY14 earnings release, which was furnished to the SEC on Form 8-K on May 5, 2014 and is posted on CareFusion’s website at www.carefusion.com under the Investors tab. The Form 8-K also includes a discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the company’s financial condition and results of operations. 3 On August 8, 2013 CareFusion announced a $750 million share repurchase program. Outlook for diluted weighted average shares outstanding reflects the impact of expected repurchases during fiscal 2014. In connection with the Q2FY14 earnings release on February 3, 2014, the company indicated that it expected diluted weighted average shares outstanding to be slightly below 215 million shares for fiscal 2014. © 2014 CareFusion Corporation or one of its subsidiaries. All rights reserved.